Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats [Behavioral Pharmacology]

Departments of Pharmaceutics (S.H.K., T.I.K., E.C.B., S.R.R.K., C.R.M., A.S.), Translational Drug Development Core (S.H.K., S.R.R.K., C.R.M., A.S.), Medicinal Chemistry (S.O., F.L., C.R.M.), and Pharmacodynamics (S.O., L.F.R., L.R.G.-J., V.L.C.P., A.P., N.P.H., L.R.M., J.L.W., T.H.), College of Pharmacy, University of Florida, Gainesville, Florida; Department of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, Alabama (S.O.); Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina (F.L.); Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland (A.H.); and Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center at Amarillo, Amarillo, Texas (L.R.M., J.L.W., T.H.)

留言 (0)

沒有登入
gif